Retatrutide and muscle loss: what the trials show

Key takeaways

• Retatrutide drives the biggest weight loss of any obesity drug tested so far: about 24 percent of body weight at the top 12 mg dose over 48 weeks in its phase 2 trial .
• More total loss means more lean tissue lost in absolute terms, but the share is not worse. Retatrutide's own body-composition substudy reported that its proportion of lean-mass loss was similar to other obesity drugs .
• Across the class, about a quarter of the weight lost on these drugs is lean tissue on a DXA scan, the same split as placebo and dieting in the tirzepatide SURMOUNT-1 substudy .
• Two levers have trial evidence: enough protein and resistance training. In a controlled deficit, a higher-protein group of young men who lifted gained 1.2 kg of lean mass while losing 4.8 kg of fat ; dieting older adults who added resistance work lost about 2 to 3 percent lean versus about 5 percent on aerobic exercise alone .
• Retatrutide is still investigational. It is not FDA approved and was in phase 3 trials as of July 2026 .

The muscle loss is real, and it is the normal cost of big weight loss

The trials measured this with DXA, the same body-composition scan used for bone density. It splits weight change into fat mass and lean (fat-free) mass. Here is what the substudies of retatrutide and its two closest rivals actually found.

• Enough protein. In a controlled four-week trial in young men, those in a steep 40 percent energy deficit who lifted and ate more protein gained about 1.2 kg of lean mass and lost 4.8 kg of fat, while a lower-protein group at the same deficit held lean mass roughly flat and lost less fat . That was young men over a short window, so it points to the protein-plus-lifting direction rather than a number an older or mixed GLP-1 audience should bank on.
• Resistance training. Among dieting older adults, the groups that added resistance work lost about 2 to 3 percent of their lean mass, versus about 5 percent for the group doing only aerobic exercise .

Why retatrutide raises the stakes even when the split is the same

Retatrutide does not appear to burn through muscle faster than other weight-loss drugs. The fraction of the loss that is lean tissue looks ordinary. The reason muscle comes up more with this one is arithmetic.

In phase 2 the top dose took off about 24 percent of body weight over 48 weeks , and the phase 3 TRIUMPH trials went higher still. A normal one-quarter lean share of a very large loss is a bigger absolute amount of muscle, and it comes off inside a year. How big the loss gets is the real driver here, not a special muscle-wasting effect.

What retatrutide's own body-composition data says

The clearest retatrutide-specific scan data comes from a substudy of its phase 2 type 2 diabetes trial, not the obesity trial. There, 189 people were enrolled for DXA scans over 36 weeks, with dulaglutide (an older diabetes GLP-1) and placebo as comparators . Fat mass fell hard: down about 23 percent from baseline at the 12 mg dose, and roughly 19 percentage points more than placebo.

On lean mass, the authors did not publish a separate kilogram figure in the summary. They reported that the proportion of lean-mass loss to total weight loss was similar to other obesity treatments, and concluded the data offered reassurance that a greater share of lean mass is not lost with retatrutide despite the larger overall weight loss .

A quarter of the loss being lean is normal for fast weight loss

The cleanest read comes from tirzepatide. In the SURMOUNT-1 body-composition substudy (160 people, DXA at 72 weeks), fat mass fell about 34 percent and lean mass about 11 percent, and about a quarter of the total weight lost was lean tissue, on both tirzepatide and placebo . The drug did not tilt the fat-to-lean split of the loss compared with diet.

Semaglutide looks similar. In the STEP-1 substudy over 68 weeks, fat mass fell about 19 percent and lean mass about 10 percent, so lean tissue actually rose about 3 points as a share of body weight . In other words, the fat-to-lean ratio these drugs produce is what any fast weight loss produces in people who are not lifting.

DXA lean mass is not pure muscle, which is worth knowing if a scary lean-mass number on a scan has you worried. Direct muscle measurement (D3-creatine dilution) reads systematically lower than DXA lean mass, because that reading also counts water, glycogen, and organ tissue, and it tracks strength and fall risk better than DXA does . The class-wide deep dive gets into why that gap matters.

What actually helps you keep muscle while the weight drops

The levers are the same whichever drug is doing the work, and none of them come from the pen. Getting enough protein and doing resistance training are the two with trial support (the protein and exercise trials in the table above). Neither depends on a prescription.

There is a trap specific to these drugs worth naming. They work by cutting appetite, so if protein just scales down with everything else you eat less of, it can quietly fall below what holds muscle in a deficit. Protein has to be chosen deliberately rather than left to whatever appetite is still around.

For the class-wide detail on how much protein and what kind of training, see GLP-1 and muscle loss. For why the scale weight is the wrong target, body recomposition versus weight loss. And on the protein side, protein, leucine, and hypertrophy.

The honest bottom line

Retatrutide takes off more weight than anything else in the class, and yes, some of that is muscle. The share is ordinary, about a quarter of the weight, and the drug's own scan data does not show it eating more lean tissue than its rivals. The size of the loss is what makes protecting muscle matter, and the two levers that work, protein and resistance training, do not come from the drug.

One thing to keep straight while you read any of this: retatrutide is still an investigational drug in phase 3 trials as of July 2026, not an approved medicine, so the current status is worth checking at the ClinicalTrials.gov record before you read too much into any headline .

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 8 entries, all primary canon (PubMed, PubMed Central, and ClinicalTrials.gov records from the New England Journal of Medicine, the Lancet Diabetes and Endocrinology, Diabetes Obesity and Metabolism, the Journal of the Endocrine Society, the American Journal of Clinical Nutrition, and the Journal of Cachexia, Sarcopenia and Muscle), last reviewed 2026-07-13.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Body-recomp simulator overview - Public overview of the Pro body-recomposition simulator.

Frequently asked questions

Does retatrutide cause more muscle loss than other weight-loss drugs?

Not as a share of the weight lost. Retatrutide's own body-composition substudy reported that its proportion of lean-mass loss was similar to other obesity treatments. Because retatrutide takes off more total weight than other drugs, the absolute amount of lean tissue lost is larger, but the fat-to-lean split of the loss looks ordinary, about a quarter lean, the same as dieting.

Can you avoid losing muscle on retatrutide?

You cannot avoid all of it, because some lean-tissue loss comes with any large, fast weight loss. Two levers have trial evidence for keeping more of it: getting enough protein and doing resistance training. In controlled trials, a higher-protein group that lifted gained lean mass while losing fat, and dieting adults who added resistance work lost less lean mass than those doing aerobic exercise alone.

Is retatrutide FDA approved?

No. As of July 2026 retatrutide is investigational and not FDA approved. It is being studied in the phase 3 TRIUMPH program. Its status can change, so the current position is worth checking on ClinicalTrials.gov or the FDA before relying on any headline.